Optimizing blood-brain barrier permeability in KRAS inhibitors: A structure-constrained molecular generation approach
Kirsten rat sarcoma viral oncogene homolog (KRAS) protein inhibitors are a promising class of therapeutics, but research on molecules that effectively penetrate the blood-brain barrier (BBB) remains limited, which is crucial for treating central nervous system (CNS) malignancies. Although molecular...
Saved in:
| Main Authors: | Xia Sheng, Yike Gui, Jie Yu, Yitian Wang, Zhenghao Li, Xiaoya Zhang, Yuxin Xing, Yuqing Wang, Zhaojun Li, Mingyue Zheng, Liquan Yang, Xutong Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Journal of Pharmaceutical Analysis |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2095177925001546 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting KRAS: from metabolic regulation to cancer treatment
by: Yanyan Shi, et al.
Published: (2025-01-01) -
Elevated KRAS protein level is associated with better survival in pancreatic cancer
by: S. M. Stålberg, et al.
Published: (2025-07-01) -
KRAS4B is required for placental development
by: Marie-Albane Minati, et al.
Published: (2025-08-01) -
The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis
by: Rui Zhao, et al.
Published: (2024-11-01) -
Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer
by: Nawaz Khan, et al.
Published: (2025-07-01)